Author
Listed:
- Ajibola Monisola Umarudeen
- Mohammed Garba Magaji
- Ferhat Khan
- Abdulhakim Abubakar
Abstract
The therapeutic gap arising from high global incidence of depressive disorders and the efficacy and toxicity shortcomings of existing antidepressant drugs indicate a need to further search the plant kingdom with the goal of discovering novel antidepressant pharmacotherapeutic agents. Crude 50% ethanol Terminalia catappa (CETC), Tapinanthus dodoneifolius (CETD) and Bryophyllum pinnatum (CEBP) leaf extracts were investigated for their acute antidepressant activity on the forced swim (FST) and tail suspension (TST) tests. Groups of mice (n = 6) were each exposed to the tests 1 hour following oral administration of distilled water (10 ml/kg), extracts (125, 250 and 500 mg/kg body weight) and fluoxetine (20 mg/kg), using the mean immobility time as endpoint. Qualitative phytochemical analysis of these crude extracts indicated the presence of alkaloids, cardiac glycosides, saponins, phenolic compounds, tannins, steroids, carbohydrates, flavonoids, terpenoids and anthraquinones. Compared to distilled water treatments (FST, 84.16 ±3.92; TST, 82.85 ±5.84), CETC (FST, 84.17 ±4.44, 71.67 ±1.89, & 44.31 ±8.23*; TST, 79.03 ±2.62, 74.10 ±3.11, & 52.57 ±6.00*) and CEBP (FST, 77.02 ±2.70, 66.11 ±4.42 & 49.99 ±4.20*; TST, 69.51 ±7.24, 49.73 ±11.85* & 46.39 ±5.68**) treatments caused dose-dependent and significant (P
Suggested Citation
Ajibola Monisola Umarudeen & Mohammed Garba Magaji & Ferhat Khan & Abdulhakim Abubakar, 2023.
"Acute Antidepressant Activity Investigation of Selected African Medicinal Plants in Mice: A Preliminary Study,"
European Journal of Pharmaceutical Research, European Open Science Publishing, vol. 3(5), pages 1-6, September.
Handle:
RePEc:epw:pharma:v:3:y:2023:i:5:id:766
DOI: 10.24018/ejpharma.2023.3.5.66
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:pharma:v:3:y:2023:i:5:id:766. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support Team (email available below). General contact details of provider: https://eu-opensci.org/index.php/pharma .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.